REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs RP 5063 (Primary) ; Aripiprazole
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Acronyms REFRESH
- Sponsors Reviva Pharmaceuticals
- 09 Apr 2013 Positive topline results reported in Reviva Pharmaceuticals media release.
- 09 Apr 2013 Results are expected to be reported at the New Clinical Drug Evaluation Unit (NCDEU) annual meeting on May 28-31 2013, according to a Reviva Pharmaceuticals media release.
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History